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To	 quantify	 the	 effect	 of	 hospital	 and	 community-based	
transmission	and	control	measures	on	Clostridium difficile 
infection	(CDI),	we	constructed	a	transmission	model	within	
and	 between	 hospital,	 community,	 and	 long-term	 care-fa-
cility	 settings.	 By	 parameterizing	 the	model	 from	 national	








and	 community	 sources,	 these	 transmission	 routes	 have	
a	 substantial	 effect	 on	hospital-onset	CDI	because	of	 the	
larger	reservoir	of	hospitalized	carriers	and	persons	in	the	
community.	Asymptomatic	carriers	and	community	sources	
should	 be	 accounted	 for	 when	 designing	 and	 evaluating	
control	interventions.
Infection with the nosocomial pathogen Clostridium dif-ficile is a major risk in healthcare settings and long-term 
care facilities (LTCFs) and has an increasing prevalence in 
the broader community. Infection is diagnosed in >250,000 
hospitalized persons annually in the United States (1). Col-
onization of the gut microbiota with C. difficile can be in-
nocuous and asymptomatic. However, antimicrobial drugs 
disrupt the normal intestinal microbial architecture and can 
enable proliferation of C. difficile (2). An insufficient host 
antibody response to C. difficile toxins A and B can then 
lead to C. difficile infection (CDI). CDI is a severe diarrhe-
al disease that is concentrated among elderly persons and 
those with extended hospital stays or residing in LTCFs. 
The relative risk for CDI, given recent antimicrobial drug 
exposure, differs greatly among antimicrobial drug classes 
and ranges from no relative risk when receiving tetracy-
clines to a 20-fold relative risk when receiving clindamycin 
(2). Despite an increasing interest in C. difficile biology and 
the epidemiology of CDI, fundamental questions about res-
ervoirs and routes of transmission remain unanswered.
Molecular typing and contact tracing studies have esti-
mated that 10%–38% of CDI cases that occur >48 hours af-
ter hospital admission (termed hospital-onset CDI) can be 
attributed to transmission from known symptomatic con-
tacts within the hospital (3–6). These estimates suggest that 
a substantial proportion of CDI arises from other sources, 
such as transmission from patients with asymptomatic col-
onization or community acquisition (3,5,7,8). The relative 
role of these routes of transmission to the epidemiology of 
C. difficile is crucial for determining effectiveness of hos-
pital-based measures to control infection. In addition, tox-
in-targeting treatments, such as vaccines, nontoxigenic C. 
difficile, and monoclonal antibodies, might protect against 
CDI but are unlikely to prevent asymptomatic colonization 
with C. difficile (9). To predict the effectiveness of these 
emerging therapies, it is critical to understand the role of 
asymptomatic carriers in CDI epidemiology.
Mathematical models of C. difficile colonization have 
generated insights regarding the epidemiologic role of 
antimicrobial drugs on CDI outbreaks (10). Such models 
have also quantified the effect of hospital-based control in-
terventions (11–14) and demonstrated the crucial roles of 
asymptomatic colonization and patients with exposure be-
fore hospital admission in sustaining hospital transmission 
(7,13). Most studies have focused on the hospital setting. 
To fully understand the epidemiology of the pathogen and 
to inform decisions regarding control strategies, it is crucial 
to quantify the relative transmission of C. difficile in the 
hospital and in the broader community (8).
To evaluate the relative role of asymptomatic hos-
pital transmission, symptomatic hospital transmission, 
LTCF transmission, and community transmission, we in-
tegrated diverse clinical and epidemiologic data into a dy-
namic model of C. difficile transmission within and among 
hospitals, LTCFs, and community settings in the United 
States. We parameterized our model by using Medicare 
and Healthcare Cost and Utilization Project databases and 
data from published epidemiologic and clinical research. 
To estimate infectivity of symptomatic and asymptomatic 
Quantifying Transmission of  
Clostridium difficile within and  
outside Healthcare Settings









patients in the hospital; corresponding infectivity of per-
sons in LTCFs and in the community; and average risks for 
acquiring C. difficile in the hospital, LTCF, and the com-
munity, we fit our model to estimated toxigenic C. difficile 
colonization and CDI incidence in each of these settings. 
Furthermore, we calculated the effect on CDI incidence of 
targeting key aspects of CDI epidemiology with control in-
terventions in each of the 3 settings.
Methods
Definitions
We refer to acquisition of C. difficile from human sources 
as C. difficile transmission and acquisition of C. difficile 
from nonhuman sources as nonhuman acquisition. Asymp-
tomatic persons carrying C. difficile are referred to as colo-
nized. Persons carrying C. difficile and symptomatic for 
diarrheal disease associated with C. difficile are referred to 
as persons with CDI.
Model Structure
Previous models have focused almost exclusively on the 
hospital setting (7,8,10,12). We constructed a new model 
that encompasses C. difficile transmission and symptomat-
ic CDI within a hospital, an LTCF, and an associated mid-
sized community and quantifies patient movement between 
these settings. We parameterized our model with data from 
a combination of sources, including published literature, 
the US Census, national hospital and LTCF surveys, and 
the Healthcare Cost and Utilization Project and Medicare 
databases (online Technical Appendix, http://wwwnc.cdc.
gov/EID/article/22/4/15-0455-Techapp1.pdf).
We structured our model in compartments (Figure 1) 
composed of patients who are currently receiving antimi-
crobial drugs, those who have a history of antimicrobial 
drug use and an increased risk for CDI, or those who do 
not have a recent history of receiving antimicrobial drugs. 
Consistent with clinical observations (15), we assumed that 
the increased risk for CDI after antimicrobial drug use re-
verted to normal in an average of 45 days. Uncolonized 
patients could become asymptomatically colonized with 
C. difficile because of transmission from asymptomatic 
patients, transmission from patients with CDI, or through 
acquisition from background sources in the community. 
Asymptomatically colonized patients could remain asymp-
tomatic, spontaneously clear their colonization, or develop 
symptomatic CDI. Patients with CDI could recover and be 
at temporarily increased risk for recolonization, could re-
cover and remain colonized and at risk for recurrence, or 
could die from the disease. We included 3 CDI and recur-
rence classes, each with a successively higher likelihood of 
recurrence, to reflect clinical observations of the increas-
ing likelihood of recurrence after multiple CDI episodes 
(16–18). We assumed that all patients with CDI were first 
asymptomatically colonized before symptoms developed.
We embedded this epidemiologic model within a model 
of patient flow between the hospital, LTCF, and community 
(Figure 2), parameterized from national hospital and long-
term-care-facility survey data. Patients with CDI remained 
hospitalized for an additional 3.1 days (95% CI 2.3–4.0 days) 
(19–21). Patients with CDI had a 96% (95% CI 93%–99%) 
probability of being given a diagnosis and subjected to isola-
tion protocols that reduced transmission by 53% (95% CI 
37%–72%) (22–25). We further assumed that persons in the 
community and in an LTCF in whom CDI developed were 
hospitalized with probabilities of 26% (95% CI 23%–28%) 
and 27% (95% CI 23%–32%), respectively (Table 1) (26,27).
Demographics
To represent demographically stratified CDI risk between 
the 3 settings, we modeled 5 demographic groups: persons 
<50 years of age, those 50–65 years of age without concur-
rent conditions, those 50–65 years of age with concurrent 
conditions, those >65 years of age without concurrent con-
ditions, and those >65 years of age with concurrent condi-
tions. Therefore, our full model consisted of base epide-
miology (Figure 1) applied to each of the 5 demographic 
groups, and each group populated and moved between the 
hospital, LTCF, and the community (Figure 2) at rates cali-
brated from published C. difficile literature, US hospital 
discharge and census data, and Medicare and Healthcare 
Cost and Utilization Project databases (online Technical 
Appendix Table 4). We assumed that colonized patients 
with concurrent conditions are at greater risk for develop-
ment of CDI (online Technical Appendix).
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We specified 5 C. difficile transmission rates: 1) the base 
CDI rate at which patients without a diagnosis and symp-
tomatic CDI transmit in the hospital, 2) the base asymp-
tomatic rate at which asymptomatically colonized patients 
transmit in the hospital, 3) the LTCF transmission rate rep-
resenting the relative infectivity of persons in LTCFs com-
pared with patients in the hospital, 4) the community trans-
mission rate representing the relative infectivity of persons 
in the community compared with patients in the hospital, 
and 5) the rate of C. difficile acquisition from nonhuman 
reservoirs. We further defined the force of colonization as 
the rate at which uncolonized patients become asymptom-
atically colonized with C. difficile and specified 3 separate 
force-of-colonization rates: 1) the hospital, 2) LTCF, and 
3) the community.
For the force of colonization in the hospital, we 
specified that nonisolated symptomatic patients with CDI 
transmit at the base CDI rate, that isolated patients with 
CDI transmit at the base CDI rate multiplied by the prob-
ability that isolation measures are insufficient, and that 
asymptomatically colonized patients transmit at the base 
asymptomatic rate. We assumed direct contact mixing 
and density-dependent transmission, which is consistent 
with the observation that larger hospitals have greater 
CDI incidence than smaller hospitals (36). Environmental 
contamination and transmission mediated by healthcare 
workers were implicitly included by our calibration of 
the base CDI rate and the base asymptomatic rate. Hos-
pital hygiene was separated into 2 components: overall 
hospital hygiene, which influenced transmission from as-
ymptomatically colonized patients and from undiagnosed 
patients with CDI; and the probability of, and effective-
ness of, enhanced isolation protocols for patients given a 
diagnosis of CDI.
For the force of colonization in the LTCF, we made 3 
assumptions. First, enhanced isolation protocols were not 
available. Second, patients with CDI transmit at the base 
CDI rate multiplied by the LTCF transmission rate modi-
fier. Third, asymptomatically colonized patients transmit at 
the base asymptomatic rate multiplied by the LTCF trans-
mission rate modifier.
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For the force of colonization in the community, we 
assumed that C. difficile could be acquired from nonhu-
man reservoirs (37), that patients with CDI transmit at 
the base CDI rate multiplied by the community transmis-
sion rate modifier, and that asymptomatically colonized 
patients transmit at the base asymptomatic rate multi-
plied by the community transmission rate modifier. Be-
cause there are insufficient published data with which to 
statistically differentiate between human transmission in 
the community and nonhuman acquisition, we estimat-
ed the force of colonization directly during our model 
calibration and then calculated the upper bounds for the 
community transmission rate modifier and for the rate of 
nonhuman acquisition.
Although age, history of antimicrobial drug use, and 
concurrent conditions are predictors of diarrheal CDI, 
they are not predictors of asymptomatic C. difficile colo-
nization (38,39). Therefore, we assumed that the rate at 
which symptomatic CDI developed in colonized patients 
was dependent on age, antimicrobial drug use, concurrent 
conditions, and hospitalization status. Transmission pa-
rameters and force of colonization were independent of 





Table 1. Epidemiologic	and	clinical	model	parameters	for	infection	with	Clostridium difficile* 
Parameter	description Prior	rate	(95%	CI)† Posterior	rate	(95%	CI)† Reference 
Epidemiology    
All-cause	CDI	mortality	rate,	%   (28) 
  Age,	y    
 <50 4.7	(2.6–7.6) 4.5	(2.6–7.5)  
 50–64 12	(8.7–16) 12	(8.5–16)  
 >65 16.6	(14–19) 17	(14–19)  
 Rate	at	which	patients	complete	antimicrobial	drug	
course 
0.22	(0.17–2.29) 0.22	(0.17–2.29) (29) 
  Rate	at	which	recurrence	develops	in	recovered	
patients 
0.13	(0.24–1) 0.2	(0.32–1.05) (30) 
  Rate	at	which	patients	not	receiving	antimicrobial	drugs	
at	increased	risk	for	CDI	revert	to	normal	risk 
0.038	(0.012–0.062) 0.033	(0.014–0.056) (15) 
  Rate	of	recovery	from	CDI 0.099	(0.090–0.11) 0.099	(0.092–0.11) (22) 
  Probability	that	a	patient	recovering	from	primary	CDI	
will	have	>1	recurrence 
22	(13–34) 24	(15–36) (16,17) 
  Probability	that	a	patient	recovering	from	a	first 
recurrence	will	have	a	second	recurrence 
33	(19–48) 34	(20–48) (16,17) 
  Probability	that	a	patient	recovering	from	multiple	
recurrences	will	have	an	additional	recurrence 
56	(42–70) 56	(41–68) (17,18) 
  Relative	risk	for	CDI	developing	while	a	patient	receives	
antimicrobial	drugs 
8.9	(4.9–13.) 8.3	(4.2–12) (2,15) 
  Relative	risk	for	CDI	among	persons	50–65	y	of	age	vs.	
those	<50	y	of	age 
2.2	(1.4–3.4) 2.2	(1.5–3.0) (31) 
  Relative	risk	for	CDI	among	persons	>65	y	of	age	
compared	with	those	<50	y	of	age 
2.9	(1.9–4.4) 3.2	(2.1–4.3) (31) 
  Spontaneous	clearance	of	asymptomatic	C. difficile 
colonization 
0.020	(0.015–0.025) 0.021	(0.016–0.026) (32) 
Hospital	protocols    
 All-cause fraction of community-onset	CDI	in	patients	
who	are	hospitalized 
0.26	(0.23–0.28) 0.26	(0.23–0.28) (26) 
 All-cause	fraction	of	LTCF-onset	CDI	in	patients	who	
are	hospitalized 
0.27	(0.23–0.32) 0.27	(0.23–0.32) (27) 
 Increased	attributable	length	of	stay	for	hospitalized	
patients	with	CDI 
3.1	(2.3–4.0) 3.1	(2.3–4.1) (19–21) 
 Effectiveness	of	enhanced	infection	control	measures	in	
reducing	transmission 
53	(37–72) 52	(37–68) (22,23) 
 Probability	that	a	patient	with	CDI	is	properly	identified	
and	given	enhanced	infection	control	measures 
0.96	(0.93–0.99)‡ 0.96	(0.94–0.99) (24,25) 
Antimicrobial	drug	use	rates    
 Prescription	rate	among	persons	in	community   (33,34) 
   Age,	y    
  <50 0.0013	(0.00095–0.0017) 0.0014	(0.00095–0.0018)  
  50–64 0.0014	(0.00097–0.0018) 0.0014	(0.00097–0.0017)  
  >65 0.0017	(0.0013–0.0021) 0.0017	(0.0013–0.0022)  
 Prescription	rate	among	patients	in	hospital 0.37	(0.22–0.66) 0.37	(0.21–0.68) (29) 
 Prescription	rate	among	patients	in	LTCF 0.0054	(0.0027–0.009) 0.0052	(0.0026–0.0087) (35) 
*CDI,	C. difficile infection;	LTCF,	long-term	care	facility.	 
†Parameter	rates	are	per	day	unless	otherwise	indicated. 
‡A	total	of	73%	of	sites	initiated	protocols	before	laboratory	confirmation	and	27%	initiated	protocols	after	confirmation.	Sensitivity	was	86%	for	




We used the Markov Chain Monte Carlo Metropolis al-
gorithm (40) to calibrate our stochastic model and com-
bined prior parameter densities (Table 1) with epidemio-
logic data, including asymptomatic prevalence and CDI 
incidence in the hospital, LTCF, and community (online 
Technical Appendix Table 2). This analysis yielded an 
ensemble of 1,000 parameter sets that estimated the joint 
posterior distribution for parameters with prior literature 
estimates (Table 1) for the 5 transmission parameters and 
for the base rate at which CDI developed in asymptom-
atically colonized persons (Table 2). Details of coding, 
the stochastic model, and calibration are provided in the 
online Technical Appendix.
Epidemiologic Analysis
To estimate relative infectivity of a hospitalized patient with 
CDI compared with a hospitalized asymptomatically colo-
nized patient, accounting for isolation protocols, we com-
puted the ratio of 1) the base CDI transmission rate from a 
hospitalized patient with CDI multiplied by the probability 
that the patient is either not given a diagnosis or that isolation 
protocols are improperly implemented to 2) the base asymp-
tomatic transmission rate from a hospitalized, asymptomati-
cally colonized patient. To generate a posterior distribution 
for this ratio, we repeated this calculation for each of the 
1,000 runs in our posterior sample. To estimate the average 
risk for a person to become exposed to and colonized with C. 
difficile, for each of the runs, we computed the average force 
of colonization within the hospital, community, and LTCF.
To estimate an upper bound for the community 
transmission rate and for nonhuman acquisition, we first 
computed the daily average community force of coloniza-
tion, which represents the sum of C. difficile transmission 
from other persons in the community plus acquisition from 
nonhuman reservoirs. By setting the nonhuman acquisition 
rate to 0, we calculated an upper bound for the commu-
nity transmission rate. Likewise, by setting the community 
transmission rate to 0, we calculated an upper bound for 
nonhuman acquisition. We repeated this step for each of 
the 1,000 runs and generated posterior distributions for the 
upper bounds of the community transmission rate and the 
nonhuman acquisition rate.
Control Strategy Analysis
To quantify the effect of transmission control interventions 
on CDI incidence, we varied each of the following factors: 
CDI diagnosis rate of a hospitalized patient with CDI, ef-
fectiveness of isolation protocols for a patient given a diag-
nosis, overall hospital hygiene, improvements in commu-
nity transmission, and improvements in LTCF transmission 
across a range from 0 to double the model-fitted maximum 
likelihood estimate and while sampling all other model pa-
rameters from their posterior distributions. We used linear 
regression to determine the reduction for hospital-onset CDI, 
community-onset CDI, and LTCF-onset CDI incidence per 
1% improvement in each transmission control intervention.
To compute the effect of different classes of antimicro-
bial drugs on CDI incidence, we varied the antimicrobial 
drug risk ratio in the hospital from 1, which is representative 
of low-risk antimicrobial drugs (e.g., tetracyclines), to 20, 
which is representative of high-risk antimicro- bial drugs 
(e.g., clindamycin) (2). While varying the antimicrobial 





Table 2. Calibrated	posterior	estimates	of	previously	unknown	epidemiologic	parameters	for	infection	with	Clostridium difficile* 
Parameter	description  Posterior	rate	(95%	CI) 
Hospital	force	of	colonization† 0.023	(0.017–0.032) 
Base	CDI	transmission	rate	within	hospital† 1.2	×	102 (0.65–2.1	×	102) 
Base	CDI	transmission	rate	within	hospital	accounting	for	isolation/control	measures† 6.0	×	103 (3.6–9.7	×	103) 




LTCF	force	of	colonization† 3.7	×	103 (0.96–7.7	×	103) 
LTCF	transmission	rate,	relative	to	hospital‡ 0.13	(0.068–0.22) 
LTCF	transmission	rate,	relative	to	hospital,	accounting	for	hospital	CDI	isolation/control	measures‡ 0.27	(0.13–0.51) 
Community	force	of	colonization† 1.2	×	103 (0.50–2.3	×	103) 




Rate of community	acquisition	from	nonhuman	reservoirs§ 1.2	×	103 (0.50–2.3	×	103) 
Base	rate	of	CDI	developing	in	hospital†¶ 2.1	×	104 (1.0–4.7	×	104) 
Base	rate	of	CDI	developing	in	LTCF†¶ 8.6	×	105 (1.1–22	×	105) 
Base	rate	of	CDI	developing	in	community†¶ 6.3	×	106 (2.9–12	×	106) 
Base	rate	of	CDI	developing	given	concurrent	conditions†¶ 2.6	(0.78–6.8) 








community and LTCF antimicrobial drug risk, from their 
posterior distributions, thereby obtaining 95% CIs for our 
estimates of the effect of antimicrobial drug class on CDI 
incidence. We repeated this analysis for antimicrobial drug 
risk in the community and the LTCF. We then calculated 
changes in hospital-onset CDI, community-onset CDI, and 
LTCF CDI incidence as hospital, community, and LTCF 
risk for antimicrobial drug use were varied.
Results
Epidemiology
For within the hospital, we computed that the ratio of trans-
mission from an isolated symptomatic patient with CDI with 
transmission from an asymptomatic patient was 15 (95% 
CI 7.2–32) (Table 2). This high ratio indicates that a symp-
tomatic patient with CDI contributes more to transmission 
than does an asymptomatically colonized patient, even af-
ter accounting for C. difficile protocols. Within the LTCF, 
the transmission rate from a person with CDI to an uncolo-
nized person is 27% (95% CI 13%–51%) that of the hos-
pital, and the transmission rate from an asymptomatically 
colonized person to an uncolonized person is 13% (95% CI 
6.8%–22%) that of the hospital. Within the community, the 
transmission rate from a person with CDI to an uncolonized 
person is 0.1% (95% CI 0.062%–0.2%) that of the hospital, 
and the transmission rate from an asymptomatically colo-
nized person to an uncolonized person is 0.052% (95% CI 
0.033%–0.089%) that of the hospital (Table 2).
To estimate the average risk for a person to become ex-
posed to and be colonized with C. difficile, we computed the 
force of colonization. We calculated that an uncolonized per-
son in the hospital has a probability of 2.3% (95% CI 1.7%–
3.2%) per day of acquiring C. difficile and becoming a car-
rier (with or without symptoms); an uncolonized person in 
the community has a probability of 0.12% (95% CI 0.050%–
0.23%) per day, and a person in an LTCF has a probability 
of 0.37% (95% CI 0.096%–0.77%) per day (Table 2). These 
results provide a quantitative estimate of the average risk for 
C. difficile exposure to persons in each setting.
Control Strategy
To estimate the effect of transmission control interventions 
on CDI incidence, we computed the percentage reduction 
in hospital-onset CDI, community-onset CDI, and LTCF 
CDI per percentage improvement in hospital CDI diagnosis 
rate, effectiveness of isolation protocols, overall hospital 
hygiene, transmission in the community, and transmission 
in an LTCF (Figure 3). We found that CDI diagnosis rate, 
effectiveness of isolation, overall hospital hygiene, and 
transmission in the community, but not transmission in an 
LTCF, affected hospital-onset CDI. In addition, communi-
ty-onset CDI and LTCF CDI were not affected by hospital-
based transmission interventions.
As the relative risk for antimicrobial drug class pre-
scribed within each of the settings was increased, the CDI 
incidence likewise increased within that setting (Figure 4). 
However, there was no relationship between the antimicro-
bial drug class prescribed within a location and CDI inci-
dence in another location. Specifically, we estimated that for 
every unit increase in antimicrobial drug risk ratio, the CDI 
incidence increased by 160% (95% CI 98%–320%) in the 
hospital, 33% (95% CI 13%–83%) in the LTCF, and 6.4% 
(95% CI 3.9%–13%) in the community. These results indi-
cate that the effect of antimicrobial drug risk on CDI inci-
dence is intertwined with C. difficile transmission dynamics, 
which differ between the hospital, LTCF, and community.
Discussion
Through stochastic simulation and Bayesian model cali-
bration, we estimated C. difficile transmission rates within 
and outside the healthcare setting. We also quantified the 
effect on CDI incidence of control interventions that reduce 
these transmission rates. We found that a person with CDI 
in an LTCF transmits at a rate 27% that for a comparable 







with CDI in the community transmits C. difficile to others 
at a rate <0.1% that of a comparable patient in the hospital. 
Despite the lower community transmission rate, we found 
that because of the much larger pool of colonized persons 
in the community, interventions that reduce community 
transmission hold substantial potential to reduce hospital-
onset CDI by reducing the number of patients entering the 
hospital with asymptomatic colonization. Moreover, our 
results show that in the hospital, symptomatic CDI patients 
under isolation and infection control measures nonethe-
less transmit CDI to uncolonized patients at a rate that is 
15 times greater than that of asymptomatic carriers. This 
higher rate of transmission indicates that toxin-targeting 
treatments (such as vaccines); nontoxigenic C. difficile; 
and monoclonal antibodies, which might protect against 
symptomatic CDI but not against asymptomatic coloniza-
tion, could be effective tools for reducing not only primary 
CDI cases but also for further transmission (9).
Our epidemiologic results underscore the need for 
incorporating and understanding transmission dynamics 
within and outside healthcare settings when evaluating C. 
difficile control strategies. Although C. difficile transmis-
sion rates are lower among asymptomatically colonized 
persons, residents of LTCFs, and persons in the community 
than in hospitalized patients with symptomatic CDI, over-
all CDI incidence is driven by several factors: transmission, 
antimicrobial drug use, and underlying population health. 
We found that, per unit increase in relative antimicrobial 
drug risk, CDI incidence increases by a factor of 160% in 
the hospital and 33% in the LTCF but only by a factor of 
6.4% in the community. This finding is a consequence of 
amplification by concentration. 
When we compared patients in the hospital and LTCF 
with persons in the community, we found that patients are 
closer to each other, are more frequently receiving antimi-
crobial drugs, and tend to have poorer overall health or may 
be immunocompromised. These attributes combine to yield 
a greater risk for infection and transmission. This finding 
of amplification-by-concentration has major implications 
for antimicrobial drug risk management: those antimicro-
bial drugs strongly associated with CDI, such as clindamy-
cin, cephalosporins, and fluoroquinolones (2), will have a 
more detrimental effect on overall CDI incidence in a high-
transmission setting, such as a hospital, than they will in 
a moderate-transmission setting, such as an LTCF, or in a 
low-transmission setting, such as the community.
We found no major effect of hospital-based transmis-
sion interventions on LTCF-onset CDI or of LTCF-based 
transmission interventions on hospital-onset CDI. This 
finding suggests that although C. difficile can be introduced 
by a patient who acquired the bacteria in the hospital, CDI 
outbreaks in LTCFs are driven primarily from within and 
are best mitigated by targeted transmission interventions 
within the facility. Likewise, any interventions to reduce 
transmission within an LTCF will have limited effect on 
hospital-onset CDI because LTCF transmission interven-
tions will not influence continued introduction of C. dif-
ficile to the hospital from the community.
The control strategies we evaluated (Figure 3) are rep-
resentative of a broad range of interventions. For example, 
an improvement in hospital isolation effectiveness could 
be achieved through enhanced hospital staff adherence to 
precautions, or alternatively through an increased capacity 
to keep a patient with CDI in isolation for the duration of 
the disease. An improvement in the LTCF transmission rate 
could be achieved through an improvement to LTCF staff 
hygiene and cleanliness, through an increased availability 
of private facilities for residents, or through the isolation of 
LTCF residents with CDI.
Although there are few data with which to differentiate 
the sources of community-associated C. difficile, we were 
able to use a community C. difficile colonization study (37) 
to calibrate our model. From our calibrated model, we es-
timated the overall community force of colonization and 
calculated an upper bound for the community transmission 
rate. Future studies of similar design but with greater sta-
tistical power than the study used for our calibration (37), 
which survey healthy, nonhospitalized adults for asymp-
tomatic C. difficile carriage while differentiating commu-
nity risk factors, would provide the necessary data with 
which our model could directly quantify transmission from 
human sources and acquisition from nonhuman reservoirs.
Our analyses demonstrated that C. difficile transmission 
among healthcare settings and the community is intercon-
nected, and there are comparable effects of community-
based transmission and hospital-based transmission on hos-
pital-onset CDI. We found that the effect of antimicrobial 
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drug use on CDI incidence is modulated by transmission dy-
namics, with specific antimicrobial drugs exacerbating inci-
dence, and doing so to a greater degree in high-transmission 
settings than in low-transmission settings. These results un-
derscore the need for empirical quantification of community-
associated transmission and the need of understanding trans-
mission dynamics in all settings when evaluating C. difficile 
interventions and control strategies.
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